Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal amphotericin B in VV-ECMO patients with invasive fungal disease
ChiCTR2500109067Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Sep 2025
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of liposomal amphotericin b in invasive mycoses (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Peak total plasma amphotericin B concentration on day 2 and Mean L-AmB dose. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
liposomal amphotericin b
03
Conditions
invasive mycoses
Beyond the preview
Go deeper on ChiCTR2500109067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109067.